摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

1-[2-[(3R)-3-(3,4-dichlorophenyl)-1-(3,4,5-trimethoxybenzoyl)pyrrolidin-3-yl]ethyl]-4-phenylpiperidine-4-carboxamide;hydron;chloride

中文名称
——
中文别名
——
英文名称
1-[2-[(3R)-3-(3,4-dichlorophenyl)-1-(3,4,5-trimethoxybenzoyl)pyrrolidin-3-yl]ethyl]-4-phenylpiperidine-4-carboxamide;hydron;chloride
英文别名
——
1-[2-[(3R)-3-(3,4-dichlorophenyl)-1-(3,4,5-trimethoxybenzoyl)pyrrolidin-3-yl]ethyl]-4-phenylpiperidine-4-carboxamide;hydron;chloride化学式
CAS
——
化学式
C34H40Cl3N3O5
mdl
——
分子量
677.1
InChiKey
DAYXLOOGUORCMH-WAQYZQTGSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    6.13
  • 重原子数:
    45
  • 可旋转键数:
    10
  • 环数:
    5.0
  • sp3杂化的碳原子比例:
    0.41
  • 拓扑面积:
    94.3
  • 氢给体数:
    2
  • 氢受体数:
    6

文献信息

  • Emulsion formulations of an NK-1 receptor antagonist and uses thereof
    申请人:Heron Therapeutics, Inc.
    公开号:US10624850B2
    公开(公告)日:2020-04-21
    Disclosed herein are novel pharmaceutical formulations of a neurokinin-1 (NK-1) receptor antagonist suitable for parenteral administration including intravenous administration. Also included are formulations including both the NK-1 receptor antagonist and dexamethasone sodium phosphate. The pharmaceutical formulations are stable oil-in-water emulsions for non-oral treatment of emesis and are particularly useful for treatment of subjects undergoing highly emetogenic cancer chemotherapy.
    本文公开了一种神经激肽-1(NK-1)受体拮抗剂的新型药物制剂,适合肠外给药,包括静脉给药。还包括同时含有 NK-1 受体拮抗剂和地塞米松磷酸钠的制剂。这些药物制剂是稳定的水包油乳剂,用于非口服治疗呕吐,尤其适用于治疗正在接受高致呕吐癌症化疗的患者。
  • TRICYCLIC COMPOUND
    申请人:Takeda Pharmaceutical Company Limited
    公开号:EP2824106B1
    公开(公告)日:2016-11-23
  • SUTURES AND ANTI-SCARRING AGENTS
    申请人:Angiotech Pharmaceuticals, Inc.
    公开号:EP1978930A2
    公开(公告)日:2008-10-15
  • PHARMACEUTICAL COMPOSITION COMPRISING ANTIEMETIC COMPOUNDS AND POLYORTHOESTER
    申请人:Heron Therapeutics, Inc.
    公开号:EP2931253A1
    公开(公告)日:2015-10-21
  • electrical devices, anti-scarring agents, and therapeutic compositions
    申请人:Hunter William L.
    公开号:US20090280153A1
    公开(公告)日:2009-11-12
    Electrical devices (e.g., cardiac rhythm management and neurostimulation devices) for contact with tissue are used in combination with an anti-scarring agent in order to inhibit scarring that may otherwise occur when the devices are implanted within an animal.
查看更多